I-ACT for Children’s Collin Hovinga, PharmD, Named to FDA Advisory Panel
Collin Hovinga, PharmD, has been named to a four-year term as a member of the U.S. Food and Drug Administration’s Drug Safety and Risk Management Advisory Committee. Dr. Hovinga, SVP of Clinical and Scientific Development at I-ACT for Children, joined the organization in 2018 and plays a lead role on many of our proprietary and pre-competitive initiatives. Based in Austin, Texas, he also is a Clinical Associate Professor of Pharmacy at the University of Texas at Austin College of Pharmacy.
In his FDA Advisory Committee role, Dr. Hovinga will review and evaluate information on risk management, risk communication and quantitative evaluation of spontaneous reports for drugs for human use that fall within FDA responsibility. The committee advises the FDA Commissioner on the scientific and medical evaluation of all information gathered by the US Department of Health and Human Services and the Department of Justice with regard to the safety, efficacy and abuse potential of drugs or other substances.